Intellia Therapeutics (NTLA) AI Stock Analysis

• Market Cap: $1.57B
• Dividend Yield: N/A
• Average Volume (3M): 4.83M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.21
• Revenue Growth: 33.52%
• EPS Growth: 21.66%
• Country: US
• Employees: 403
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.83
• Shares Outstanding: 115,829,926
• 10 Day Avg. Volume: 2,381,191
• 30 Day Avg. Volume: 4,831,197
• PEG Ratio: 0.09
• Price to Book (P/B): 1.45
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.75
• Enterprise Value/Market Cap: 0.93
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -42.54
• Enterprise Value/Ebitda: -4.53
• 1Y Price Target: $17.10
• Price Target Upside: 19.75% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): -3.61
• Revenue Forecast (FY): $57.84M

• Rating: 54 Neutral
• Price Target: $14.50 ▲(1.54% Upside)
• Action: Reiterated Date: 02/27/26
• Date: Action: Reiterated 02/27/26

The score is held back primarily by weak financial performance (persistent losses, cash burn, and volatile revenue) and limited valuation support due to negative earnings. These are partly offset by improving technical momentum and an earnings-call setup that highlights a potentially pivotal HAE readout and commercialization path, though the unresolved FDA hold and safety uncertainty in the ATTR program remains a major risk.

Positive Factors

Pivotal Phase 3 readout for lonvo-z

Completing pivotal enrollment and targeting mid-2026 top-line results is a durable de‑risking event: a positive readout could validate Intellia's in vivo CRISPR platform, enable a BLA pathway and create a one‑time curative launch opportunity, materially shifting long‑term revenue prospects and strategic optionality.

High patient and physician demand

Strong, validated demand from patients and prescribers indicates a durable addressable market and favorable uptake dynamics if approved: high willingness-to-take and physician identification reduce commercial execution risk and improve the likelihood of sustainable product adoption and revenue realization.

Solid liquidity runway and modest leverage

A multi‑quarter runway and a balance sheet with low-to-moderate leverage provide durable operational flexibility to complete pivotal readouts, pursue regulatory activities and prepare for commercialization without immediate refinancing; this reduces short‑term solvency risk during key value‑creating milestones.

Negative Factors

Persistent cash burn and negative cash flow

Sustained negative operating and free cash flow is a durable constraint: continued burn depletes runway and forces reliance on external financing or partnerships, which can dilute shareholders, constrain R&D choices, and increase execution risk for later‑stage launches and follow‑on programs.

Regulatory and safety overhang on ATTR program

An unresolved clinical hold on a major cardiomyopathy trial creates long‑term program risk: delays or additional safety requirements could materially reduce the commercial opportunity for nex-z, increase development costs, and prompt broader regulatory scrutiny of in vivo CRISPR approaches across the pipeline.

Volatile revenue and persistent losses

Dependence on uneven collaboration and milestone revenue, combined with chronic losses, undermines durable earnings generation: without commercial product revenues, financial performance will remain volatile and limit reinvestment capacity, increasing the probability of future dilution or strategic dealmaking.

Intellia Therapeutics Business Overview & Revenue Model

Company Description

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

How the Company Makes Money

Intellia Therapeutics generates revenue through a combination of research collaborations, licensing agreements, and potential future product sales. The company often partners with larger pharmaceutical firms, which provide upfront payments and milestone payments tied to the achievement of specific development goals. Additionally, Intellia may receive royalties on the sales of any products developed through these collaborations. As the company advances its clinical programs and moves closer to commercialization, it may also begin to realize revenue from product sales once its therapies receive regulatory approvals. Key partnerships with organizations such as Regeneron Pharmaceuticals enhance its research capabilities and financial resources, contributing significantly to its earnings potential.

Intellia Therapeutics Financial Statement Overview

Summary

Overall financial quality is pressured by persistent large net losses, volatile/uneven revenue (including zero revenue in the latest annual period), and consistently negative operating/free cash flow. The balance sheet is a relative strength due to modest leverage, but equity has been pressured by ongoing deficits and cash has declined materially year over year.

Income Statement

Profitability remains a key weakness, with large net losses every year (2020–2025) and deeply negative profit margins in most periods. Revenue has been volatile: it grew in 2022 and 2024 but declined in 2021 and 2023, and fell to zero in 2025 (annual), reflecting high dependence on uneven collaboration/other revenue sources. A positive is that gross margin was strong in 2021–2024, indicating favorable unit economics when revenue is present, but operating costs continue to materially outweigh gross profit.

Balance Sheet

The balance sheet is a relative strength with low-to-moderate leverage, as debt-to-equity stayed modest (roughly 0.07–0.24) despite fluctuations in total debt. However, recurring net losses have driven consistently negative returns on equity and stockholders’ equity has trended down from 2022 to 2025, signaling ongoing capital consumption. Overall, solvency risk looks contained due to limited leverage, but the equity base is being pressured by persistent losses.

Cash Flow

Cash generation is weak: operating cash flow and free cash flow are consistently negative across all years, reflecting a business still funding operations through cash burn. Cash burn worsened in 2022–2023 versus 2021 and remained heavy in 2024–2025, with free cash flow declining again in 2025 (annual). A modest positive is that cash flow tracks net losses closely (free cash flow roughly in line with net income), suggesting losses are not being significantly exacerbated by non-cash working-capital swings—but the core issue remains the scale and persistence of cash burn.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	57.88M	36.27M	52.12M	33.05M
Gross Profit	0.00	47.59M	27.30M	44.55M	26.16M
EBITDA	0.00	-523.98M	-506.31M	-450.59M	-260.96M
Net Income	-412.69M	-519.02M	-481.19M	-474.19M	-267.89M
Balance Sheet
Total Assets	842.13M	1.19B	1.30B	1.52B	1.29B
Cash, Cash Equivalents and Short-Term Investments	449.88M	601.51M	912.22M	1.19B	748.69M
Total Debt	93.33M	210.20M	115.35M	130.70M	74.02M
Total Liabilities	170.73M	319.06M	250.81M	284.53M	254.22M
Stockholders Equity	671.39M	871.96M	1.05B	1.24B	1.04B
Cash Flow
Free Cash Flow	-354.66M	-354.66M	-408.07M	-391.68M	-237.79M
Operating Cash Flow	-348.88M	-348.88M	-394.09M	-333.29M	-225.03M
Investing Cash Flow	125.57M	125.57M	-31.35M	160.31M	-550.78M
Financing Cash Flow	185.75M	185.75M	130.32M	582.96M	736.69M

Intellia Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 14.28
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTLA, the sentiment is Positive. The current price of 14.28 is above the 20-day moving average (MA) of 12.68, above the 50-day MA of 11.66, and above the 200-day MA of 12.19, indicating a bullish trend. The MACD of 0.40 indicates Negative momentum. The RSI at 62.82 is Neutral, neither overbought nor oversold. The STOCH value of 90.26 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NTLA.

Intellia Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KURA	63 Neutral	$729.21M	-3.45	-65.10%	―	―	-5.18%
CMPX	58 Neutral	$1.07B	-12.87	-37.82%	―	-100.00%	-28.79%
BCAX	56 Neutral	$889.66M	-7.85	-26.64%	―	―	-103.95%
NTLA	54 Neutral	$1.57B	-3.15	-52.11%	―	33.52%	21.66%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
JANX	50 Neutral	$821.02M	-8.18	-12.48%	―	-23.37%	-42.45%
ABCL	49 Neutral	$963.86M	-6.50	-14.47%	―	7.16%	3.95%

Intellia Therapeutics Corporate Events

FDA Lifts Hold on Intellia’s MAGNITUDE-2 Trial

On January 27, 2026, Intellia Therapeutics announced that the U.S. Food and Drug Administration lifted the clinical hold on its investigational new drug application for the MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN), a hold that had been imposed on October 29, 2025 after a MAGNITUDE trial patient experienced severe liver toxicity and subsequently died. Following alignment with the FDA on protocol modifications and enhanced liver safety monitoring, Intellia plans to resume enrollment and dosing in MAGNITUDE-2, expand target enrollment from about 50 to 60 patients, and continue evaluating the efficacy and safety of a single 55 mg infusion of nex-z versus placebo; however, the separate MAGNITUDE Phase 3 trial in ATTR-CM remains on clinical hold as discussions with the agency continue, leaving a key part of the nex-z program and Intellia’s broader ATTR strategy still subject to regulatory uncertainty for patients, investigators and investors.

The most recent analyst rating on (NTLA) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.

Intellia Updates Investors on Nex-Z Trial Safety Hold

On January 9, 2026, Intellia Therapeutics updated its corporate presentation to investors, detailing the status of its CRISPR-based pipeline and providing additional disclosure on a serious safety event tied to its lead ATTR amyloidosis candidate, nexiguran ziclumeran (nex-z). The company reiterated that a patient in the Phase 3 MAGNITUDE trial for transthyretin amyloidosis with cardiomyopathy experienced Grade 4 liver transaminase elevations and increased bilirubin, triggering a protocol-mandated trial pause and prompting the U.S. Food and Drug Administration to impose a clinical hold on both the MAGNITUDE and MAGNITUDE-2 Phase 3 studies; the patient subsequently died on November 5, 2025, with the principal investigator attributing the death to septic shock from a perforated duodenal ulcer amid a complex clinical course that included acute liver injury treated with corticosteroids. Intellia reported that more than 650 patients with ATTR-CM and 47 patients with hereditary ATTR amyloidosis with polyneuropathy have been enrolled across the two trials, with Grade 4 liver enzyme elevations observed in less than 1% of MAGNITUDE participants and none in MAGNITUDE-2, and said it will update stakeholders once it has agreed with regulators on a path forward for nex-z, underscoring both the regulatory risk around its flagship ATTR program and the broader safety and development uncertainties facing first-in-class in vivo CRISPR therapies.

The most recent analyst rating on (NTLA) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Intellia Therapeutics stock, see the NTLA Stock Forecast page.